Because the PI3K-AKT pathway is critical for sustained motility when the Ras-ERK pathway is inhibited, we then investigated if either integrin β1 or β5 are required for activation of AKT following MEK suppression among parental and metastatic breast cancers. The gene discussed is MAP2K7; the disease is breast cancer.